SUBSEQUENT EVENTS	3 Months Ended
Sep. 30, 2016
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	Bremelanotide Phase 3 HSDD Topline Results – On November 1, 2016, we announced positive top-line results in our Phase 3 clinical trial program of bremelanotide as an on-demand treatment for premenopausal women diagnosed with HSDD. Bremelanotide 1.75 mg met the pre-specified co-primary efficacy endpoints of improvement in desire and decrease in distress associated with low sexual desire as measured using validated patient-reported outcome instruments. Outstanding Common Stock – Between September 30, 2016 and November 10, 2016, the Company issued 15,232,511 shares of common stock pursuant to the cashless exercise provisions of warrants at an exercise price of $0.01 per share. As of November 10, 2016, there are 62,046,764 outstanding warrants with an exercise price of $0.01 per share, all of which include cashless exercise provisions.

SUBSEQUENT EVENTS

3 Months Ended

Sep. 30, 2016

Bremelanotide Phase 3 HSDD Topline Results – On November 1, 2016, we announced positive top-line results in our Phase 3 clinical trial program of bremelanotide as an on-demand treatment for premenopausal women diagnosed with HSDD. Bremelanotide 1.75 mg met the pre-specified co-primary efficacy endpoints of improvement in desire and decrease in distress associated with low sexual desire as measured using validated patient-reported outcome instruments.

Outstanding Common Stock – Between September 30, 2016 and November 10, 2016, the Company issued 15,232,511 shares of common stock pursuant to the cashless exercise provisions of warrants at an exercise price of $0.01 per share. As of November 10, 2016, there are 62,046,764 outstanding warrants with an exercise price of $0.01 per share, all of which include cashless exercise provisions.